AU2021238951A1 - High concentration anti-Aß protofibril antibody formulations and methods of use thereof - Google Patents

High concentration anti-Aß protofibril antibody formulations and methods of use thereof Download PDF

Info

Publication number
AU2021238951A1
AU2021238951A1 AU2021238951A AU2021238951A AU2021238951A1 AU 2021238951 A1 AU2021238951 A1 AU 2021238951A1 AU 2021238951 A AU2021238951 A AU 2021238951A AU 2021238951 A AU2021238951 A AU 2021238951A AU 2021238951 A1 AU2021238951 A1 AU 2021238951A1
Authority
AU
Australia
Prior art keywords
pharmaceutical formulation
arginine
concentration
fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021238951A
Other languages
English (en)
Inventor
Yung Yueh HSU
Anjali Joshi
Hirokazu Kito
Takahiro Ozawa
Takahisa Sakaguchi
Naomi SAKURAMOTO
Pierre SOUILLAC
Nobuo Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75746958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2021238951(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of AU2021238951A1 publication Critical patent/AU2021238951A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
AU2021238951A 2020-03-20 2021-03-19 High concentration anti-Aß protofibril antibody formulations and methods of use thereof Pending AU2021238951A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062992746P 2020-03-20 2020-03-20
US62/992,746 2020-03-20
US202063027263P 2020-05-19 2020-05-19
US63/027,263 2020-05-19
PCT/IB2021/000155 WO2021186245A1 (en) 2020-03-20 2021-03-19 HIGH CONCENTRATION ANTI-Aß PROTOFIBRIL ANTIBODY FORMULATIONS AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
AU2021238951A1 true AU2021238951A1 (en) 2022-10-20

Family

ID=75746958

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021238951A Pending AU2021238951A1 (en) 2020-03-20 2021-03-19 High concentration anti-Aß protofibril antibody formulations and methods of use thereof

Country Status (28)

Country Link
US (1) US20230183328A1 (cg-RX-API-DMAC7.html)
EP (2) EP4252777B1 (cg-RX-API-DMAC7.html)
JP (2) JP7689141B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220156534A (cg-RX-API-DMAC7.html)
CN (1) CN115315251A (cg-RX-API-DMAC7.html)
AU (1) AU2021238951A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018766A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174778A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002517A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022012916A2 (cg-RX-API-DMAC7.html)
DK (1) DK4121007T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041762T3 (cg-RX-API-DMAC7.html)
FI (1) FI4121007T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251087T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072937T2 (cg-RX-API-DMAC7.html)
IL (2) IL326613A (cg-RX-API-DMAC7.html)
LT (1) LT4121007T (cg-RX-API-DMAC7.html)
MA (1) MA59082B1 (cg-RX-API-DMAC7.html)
MD (1) MD4121007T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022011101A (cg-RX-API-DMAC7.html)
PH (1) PH12022552172A1 (cg-RX-API-DMAC7.html)
PL (1) PL4121007T3 (cg-RX-API-DMAC7.html)
PT (1) PT4121007T (cg-RX-API-DMAC7.html)
RS (1) RS67249B1 (cg-RX-API-DMAC7.html)
SI (1) SI4121007T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500350T1 (cg-RX-API-DMAC7.html)
TW (1) TWI923576B (cg-RX-API-DMAC7.html)
WO (1) WO2021186245A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021310926A1 (en) 2020-07-23 2023-03-23 Othair Prothena Limited Anti-abeta antibodies
JP2024525559A (ja) 2021-07-09 2024-07-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 アルツハイマー病治療用バイオマーカー
KR20240142535A (ko) 2022-02-02 2024-09-30 에자이 알앤드디 매니지먼트 가부시키가이샤 P-tau181 수준을 사용한 치료 방법
CN120202218A (zh) 2022-11-28 2025-06-24 卫材R&D管理有限公司 使用tau PET水平的治疗方法
IL324807A (en) 2023-06-09 2026-01-01 Eisai R&D Man Co Ltd Treatment methods using anti-Abeta protofibril antibody
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
MD3672631T3 (ro) 2017-08-22 2023-09-30 Biogen Ma Inc Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
WO2020023530A2 (en) * 2018-07-24 2020-01-30 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease

Also Published As

Publication number Publication date
SI4121007T1 (sl) 2025-10-30
DK4121007T3 (da) 2025-09-22
EP4121007B1 (en) 2025-07-02
IL326613A (en) 2026-04-01
MA59082B1 (fr) 2025-09-30
CL2022002517A1 (es) 2023-03-24
JP2023518066A (ja) 2023-04-27
SMT202500350T1 (it) 2025-11-10
IL295383A (en) 2022-10-01
JP7689141B2 (ja) 2025-06-05
EP4252777B1 (en) 2026-06-17
KR20220156534A (ko) 2022-11-25
CA3174778A1 (en) 2021-09-23
JP2025111516A (ja) 2025-07-30
EP4121007A1 (en) 2023-01-25
TWI923576B (zh) 2026-05-01
FI4121007T3 (fi) 2025-09-11
MX2022011101A (es) 2022-10-03
PT4121007T (pt) 2025-09-25
CO2022012916A2 (es) 2022-09-20
US20230183328A1 (en) 2023-06-15
EP4252777A2 (en) 2023-10-04
HRP20251087T1 (hr) 2025-11-07
TW202200201A (zh) 2022-01-01
CN115315251A (zh) 2022-11-08
LT4121007T (lt) 2025-09-25
IL295383B1 (en) 2026-04-01
IL295383B2 (en) 2026-08-01
HUE072937T2 (hu) 2025-12-28
ES3041762T3 (en) 2025-11-14
EP4252777A9 (en) 2023-11-15
PL4121007T3 (pl) 2025-11-03
WO2021186245A1 (en) 2021-09-23
PH12022552172A1 (en) 2023-12-11
EP4252777A3 (en) 2024-01-24
MD4121007T2 (ro) 2025-11-30
BR112022018766A2 (pt) 2022-11-01
RS67249B1 (sr) 2025-10-31
CL2024003428A1 (es) 2025-04-11

Similar Documents

Publication Publication Date Title
EP4121007B1 (en) High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof
US20100189721A1 (en) Antibody formulations
HK1211840A1 (en) Stable, low viscosity antibody formulation
BR112012012080B1 (pt) Formulações de histidina-trealose do anticorpo t1h
TWI764097B (zh) 包含抗cd47抗體的製劑及其製備方法和用途
KR20180003452A (ko) 안정한 액체 약제학적 제제
US20250282882A1 (en) Pharmaceutical formulation comprising anti-ox40 monoclonal antibody
HK40102754A (en) High concentration anti-ass protofibril antibody formulations and methods of use thereof
HK40085437A (en) High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof
HK40085437B (en) High concentration anti-amyloid beta peptide protofibril antibody formulations and methods of use thereof
RU2846725C1 (ru) ВЫСОКОКОНЦЕНТРИРОВАННЫЕ СОСТАВЫ НА ОСНОВЕ АНТИТЕЛ К ПРОТОФИБРИЛЛАМ Аβ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR20240100493A (ko) 항-cd22 항체의 수성 제제 및 이의 용도
RU2745814C1 (ru) Водная фармацевтическая композиция левилимаба и ее применение
BR122025027938A2 (pt) FORMULAÇÕES DE ANTICORPO DE PROTOFIBRILA ANTI-Abeta DE CONCENTRAÇÃO ALTA E MÉTODOS DE USO DAS MESMAS
JP2025534054A (ja) 抗tigit抗体を含む製剤及びその使用方法
EA052372B1 (ru) Фармацевтическая композиция, содержащая моноклональное антитело к ox40
CN118076381A (zh) 改进免疫检查点抑制剂的稳定性的方法
EA045933B1 (ru) Водная фармацевтическая композиция левилимаба и ее применение
HK40059591A (en) Preparations containing anti-cd47 antibody, and preparation method and use therefor
HK1233918A (en) Stable, low viscosity antibody formulation
HK1233918A1 (en) Stable, low viscosity antibody formulation
HK1257781A1 (zh) 含抗-pd-l1抗体avelumab的水性药物制剂